세계의 내분비 치료제 시장 보고서(2025년)

Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.

The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endocrinology drugs market size has declined marginally in recent years. It will grow from $26.29 billion in 2024 to $26.2 billion in 2025 at a compound annual growth rate (CAGR) of -0.3%. The growth in the historic period can be attributed to increasing prevalence of diabetes globally, increasing government initiatives, increasing healthcare expenditure, increasing prevalence of adrenal gland disorders, a rise in demand for insulin analogs, and growth in the number of endocrinologists.

The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.37 billion in 2029 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to a growing diabetic population, increasing prevalence of endocrine disorders, a growing number of adolescents with hormonal imbalances, and rising obesity rates. Major trends in the forecast period include technological advancements, adoption of advanced drug delivery systems, integration of digital health solutions, precision medicine, and combination therapies.

The forecast of 0.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder U.S. hormone therapy access by inflating prices of recombinant insulin analogs and thyroid medication active pharmaceutical ingredients imported from France and India, resulting in delayed diabetes management and higher chronic disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.

Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca's portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.

Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endocrinology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endocrinology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endocrinology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The endocrinology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Hyperthyroidism; Hypothyroidism; Diabetes; Polycystic Ovarian Syndrome; Growth Hormone Disorders; Pituitary Gland Disorders; Other Indications
• 2) By Therapy Area: Diabetes Drugs; Thyroid Hormone Disorder Drugs; Human Growth Hormone; Testosterone Replacement Therapy; Others Therapy Areas
• 3) By Distribution Channel: Hospital pharmacies; Online Pharmacies; Retail pharmacies
• 4) By End User: Hospitals; Ambulatory Surgical Centers; Others End Users
• Subsegments:
• 1) By Hyperthyroidism: Antithyroid Medications; Radioactive Iodine Therapy; Beta Blockers
• 2) By Hypothyroidism: Levothyroxine-based Medications; Liothyronine-based Medications; Combination Hormonal Therapies
• 3) By Diabetes: Insulin Therapies; Oral Antidiabetic Drugs (OADs); GLP-1 Receptor Agonists; SGLT-2 Inhibitors; DPP-4 Inhibitors
• 4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives; Metformin; Clomiphene Citrate; Anti-Androgens
• 5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH); Growth Hormone Secretagogues; Growth Hormone Receptor Antagonists
• 6) By Pituitary Gland Disorders: Somatostatin Analogs; Gonadotropins; Dopamine Agonists
• 7) By Other Indications: Adrenal Gland Disorders; Osteoporosis; Parathyroid Disorders; Male Hormonal Imbalances
• Companies Mentioned: Johnson & Johnson Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis International AG; Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Novo Nordisk A/S; Biocon Limited; Boehringer Ingelheim International GmbH; Mylan N.V.; Sandoz International GmbH; Ipsen Pharma; Ferring Pharmaceuticals Inc.; Endocrine Pharma Private Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Endocrinology Drugs Market Characteristics

3. Endocrinology Drugs Market Trends And Strategies

4. Endocrinology Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Endocrinology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Endocrinology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Endocrinology Drugs Market Growth Rate Analysis
• 5.4. Global Endocrinology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Endocrinology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Endocrinology Drugs Total Addressable Market (TAM)

6. Endocrinology Drugs Market Segmentation

• 6.1. Global Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyperthyroidism
• Hypothyroidism
• Diabetes
• Polycystic Ovarian Syndrome
• Growth Hormone Disorders
• Pituitary Gland Disorders
• Other Indications
• 6.2. Global Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetes Drugs
• Thyroid Hormone Disorder Drugs
• Human Growth Hormone
• Testosterone Replacement Therapy
• Other Therapy Areas
• 6.3. Global Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacies
• Online Pharmacies
• Retail pharmacies
• 6.4. Global Endocrinology Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Other End Users
• 6.5. Global Endocrinology Drugs Market, Sub-Segmentation Of Hyperthyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antithyroid Medications
• Radioactive Iodine Therapy
• Beta Blockers
• 6.6. Global Endocrinology Drugs Market, Sub-Segmentation Of Hypothyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levothyroxine-based Medications
• Liothyronine-based Medications
• Combination Hormonal Therapies
• 6.7. Global Endocrinology Drugs Market, Sub-Segmentation Of Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Therapies
• Oral Antidiabetic Drugs (OADs)
• GLP-1 Receptor Agonists
• SGLT-2 Inhibitors
• DPP-4 Inhibitors
• 6.8. Global Endocrinology Drugs Market, Sub-Segmentation Of Polycystic Ovarian Syndrome (PCOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Contraceptives
• Metformin
• Clomiphene Citrate
• Anti-Androgens
• 6.9. Global Endocrinology Drugs Market, Sub-Segmentation Of Growth Hormone Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Growth Hormone (rhGH)
• Growth Hormone Secretagogues
• Growth Hormone Receptor Antagonists
• 6.10. Global Endocrinology Drugs Market, Sub-Segmentation Of Pituitary Gland Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatostatin Analogs
• Gonadotropins
• Dopamine Agonists
• 6.11. Global Endocrinology Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adrenal Gland Disorders
• Osteoporosis
• Parathyroid Disorders
• Male Hormonal Imbalances

7. Endocrinology Drugs Market Regional And Country Analysis

• 7.1. Global Endocrinology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Endocrinology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Endocrinology Drugs Market

• 8.1. Asia-Pacific Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Endocrinology Drugs Market

• 9.1. China Endocrinology Drugs Market Overview
• 9.2. China Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Endocrinology Drugs Market

• 10.1. India Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Endocrinology Drugs Market

• 11.1. Japan Endocrinology Drugs Market Overview
• 11.2. Japan Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Endocrinology Drugs Market

• 12.1. Australia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Endocrinology Drugs Market

• 13.1. Indonesia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Endocrinology Drugs Market

• 14.1. South Korea Endocrinology Drugs Market Overview
• 14.2. South Korea Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Endocrinology Drugs Market

• 15.1. Western Europe Endocrinology Drugs Market Overview
• 15.2. Western Europe Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Endocrinology Drugs Market

• 16.1. UK Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Endocrinology Drugs Market

• 17.1. Germany Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Endocrinology Drugs Market

• 18.1. France Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Endocrinology Drugs Market

• 19.1. Italy Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Endocrinology Drugs Market

• 20.1. Spain Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Endocrinology Drugs Market

• 21.1. Eastern Europe Endocrinology Drugs Market Overview
• 21.2. Eastern Europe Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Endocrinology Drugs Market

• 22.1. Russia Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Endocrinology Drugs Market

• 23.1. North America Endocrinology Drugs Market Overview
• 23.2. North America Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Endocrinology Drugs Market

• 24.1. USA Endocrinology Drugs Market Overview
• 24.2. USA Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Endocrinology Drugs Market

• 25.1. Canada Endocrinology Drugs Market Overview
• 25.2. Canada Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Endocrinology Drugs Market

• 26.1. South America Endocrinology Drugs Market Overview
• 26.2. South America Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Endocrinology Drugs Market

• 27.1. Brazil Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Endocrinology Drugs Market

• 28.1. Middle East Endocrinology Drugs Market Overview
• 28.2. Middle East Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Endocrinology Drugs Market

• 29.1. Africa Endocrinology Drugs Market Overview
• 29.2. Africa Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Endocrinology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Endocrinology Drugs Market Competitive Landscape
• 30.2. Endocrinology Drugs Market Company Profiles
  • 30.2.1. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Endocrinology Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Novo Nordisk A/S
• 31.9. Biocon Limited
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Mylan N.V.
• 31.12. Sandoz International GmbH
• 31.13. Ipsen Pharma
• 31.14. Ferring Pharmaceuticals Inc.
• 31.15. Endocrine Pharma Private Limited

32. Global Endocrinology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endocrinology Drugs Market

34. Recent Developments In The Endocrinology Drugs Market

35. Endocrinology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Endocrinology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Endocrinology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Endocrinology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer